May Neutrophil Gelatinase-Associated Lipocalin (NGAL) Level Predict Mortality in Patients with Hepatocellular Carcinoma (HCC)?

  • Ramazan DertliEmail author
  • Murat Biyik
  • Ramazan Yolacan
  • Ahmet Karakarcayildiz
  • Muharrem Keskin
  • Yusuf Kayar
  • Mehmet Asil
Original Research



Hepatocellular carcinoma (HCC) ranks fifth among the common cancers worldwide. Hepatocarcinogenesis is a multiple-phases process, which involves changes in cellular genomes including high cell proliferation.In this study, we aimed to evaluate the relationship of NGAL level at the time of diagnosis with mortality in patients diagnosed with HCC.

Material and Methods

A total of 35 patients who developed HCC on the ground of HBV(+) and 30 healthy subjects were included in the study. Barcelona Clinic Liver Cancer (BCLC), Okuda staging system, and Milan criteria were used for staging of the patients with HCC.


The mean age of all patients was 59.54 ± 11.57 years. Seventeen (48.6%) HCC patients died during 1-year follow-up. Survival of the patients who met the Milan criteria was longer (log-rank (Mantel-Cox) test, χ2 = 5.353, p = 0.021). Kaplan-Meier curve was drawn for NGAL cut-off value, mortality was found to be higher in patients with a NGAL level higher than 217.50 (log-rank (Mantel-Cox) test, χ2 = 15.540, p < 0.001).


In this study, we found that high levels of NGAL at the time of diagnosis were associated with poor prognosis in HCC patients.


ords: Hepatocellular carcinoma lipocalin-2 Neutrophil gelatinase-associated lipocalin 


Compliance with Ethical Standards

This study was conducted in accordance with the ethical standards of the Declaration of Helsinki. The ethical approval was received from the ethical committee of Necmettin Erbakan University Meram Medical Faculty.

Conflict of Interest

The authors declare that they have no conflict of interest.


  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.CrossRefGoogle Scholar
  2. 2.
    Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–91.CrossRefGoogle Scholar
  3. 3.
    Forner A, Llovet JM, Bruix J. Hepatocellularcarcinoma. Lancet. 2012;379(9822):1245.CrossRefGoogle Scholar
  4. 4.
    Huang YH, Wu JC, Chen CH, Chang TT, Lee PC, Chau GY, et al. Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int. 2005;25(2):236–41.CrossRefGoogle Scholar
  5. 5.
    Mehmet A, Dertli R. Serum soluble TWEAK concentration is decreased in patients with hepatocellular cancer and low blood levels of sTWEAK are associated with poor survival. Int J Hematol Oncol. 27(2):118–26.Google Scholar
  6. 6.
    Cabiati M, Gaggini M, Cesare MM, Caselli C, De Simone P, Filipponi F, et al. Osteopontin in hepatocellular carcinoma: a possible biomarker for diagnosis and follow-up. Cytokine. 2017;99:59–65.CrossRefGoogle Scholar
  7. 7.
    Rodvold JJ, Mahadevan NR, Zanetti M. Lipocalin 2 in cancer: when good immunity goes bad. Cancer Lett. 2012;316(2):132–8.CrossRefGoogle Scholar
  8. 8.
    Li C, Chan YR. Lipocalin 2 regulation and its complex role in inflammation and cancer. Cytokine. 2011;56(2):435–41.CrossRefGoogle Scholar
  9. 9.
    Jin D, Zhang Y, Chen X. Lipocalin 2 deficiency inhibits cell proliferation, autophagy, and mitochondrial biogenesis in mouse embryonic cells. Mol Cell Biochem. 2011;351(1-2):165–72.CrossRefGoogle Scholar
  10. 10.
    Leng X, Wu Y, Arlinghaus RB. Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J Cell Physiol. 2011;226(2):309–14.CrossRefGoogle Scholar
  11. 11.
    Lin H-H, Liao C-J, Lee Y-C, Hu K-H, Meng H-W, Chu S-T. Lipocalin-2-induced cytokine production enhances endometrial carcinoma cell survival and migration. Int J Biol Sci. 2011;7(1):74–86.CrossRefGoogle Scholar
  12. 12.
    Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, Thompson EW, et al. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer. 2007;120(11):2426–34.CrossRefGoogle Scholar
  13. 13.
    Furutani M, Arii S, Mizumoto M, Kato M, Imamura M. Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. Cancer Lett. 1998;122(1):209–14.CrossRefGoogle Scholar
  14. 14.
    Kubben FJ, Sier CF, Hawinkels LJ, Tschesche H, van Duijn W, Zuidwijk K, et al. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer. 2007;43(12):1869–76.CrossRefGoogle Scholar
  15. 15.
    Barresi V, Vitarelli E, Bonetti LR, Tuccari G, Barresi G. Diagnostic value of neutrophil gelatinase-associated lipocalin (NGAL) immunoexpression in follicular-patterned lesions of the thyroid gland. Virchows Archiv. 2012;460(3):319–25.CrossRefGoogle Scholar
  16. 16.
    Ozemir IA, Aslan S, Eren T, Bayraktar B, Bilgic C, Isbilen B, et al. The diagnostic and prognostic significance of serum neutrophil gelatinase-associated lipocalin levels in patients with colorectal cancer. Chirurgia (Bucharest, Romania: 1990). 2016;111(5):414–21.CrossRefGoogle Scholar
  17. 17.
    Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell. 2002;10(5):1033–43.CrossRefGoogle Scholar
  18. 18.
    Patil MA, Chua M-S, Kuang-Hung P, Lin R, Lih C-J, Cheung S-T, et al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene. 2005;24(23):3737.CrossRefGoogle Scholar
  19. 19.
    Lee E-K, Kim H-J, Lee K-J, Lee H-J, Lee J-S, Kim D-G, et al. Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/Akt signaling. Int J Oncol. 2011;38(2):325–33.CrossRefGoogle Scholar
  20. 20.
    Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients. Cancer. 1985;56(4):918–28.CrossRefGoogle Scholar
  21. 21.
    Llovet JM, Brú C, Bruix J, editors. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in liver disease; 1999: © 1999 by Thieme Medical Publishers, Inc.Google Scholar
  22. 22.
    Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–700.CrossRefGoogle Scholar
  23. 23.
    Stejskal D, Karpíšek M, Humenanska V, Hanulova Z, Stejskal P, Kusnierova P, et al. Lipocalin-2: development, analytical characterization, and clinical testing of a new ELISA. Horm Metab Res. 2008;40(06):381–5.CrossRefGoogle Scholar
  24. 24.
    Giasson J, Hua Li G, Chen Y. Neutrophil gelatinase-associated lipocalin (NGAL) as a new biomarker for non-acute kidney injury (AKI) diseases. Inflamm Allergy Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy). 2011;10(4):272–82.Google Scholar
  25. 25.
    Mir SU, Jin L, Craven RJ. Neutrophil gelatinase-associated lipocalin (NGAL) expression is dependent on the tumor-associated sigma-2 receptor S2RPgrmc1. J Biol Chem. 2012;287(18):14494–501.CrossRefGoogle Scholar
  26. 26.
    Yang J, Moses MA. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle. 2009;8(15):2347–52.CrossRefGoogle Scholar
  27. 27.
    Bouchet S, Bauvois B. Neutrophil gelatinase-associated lipocalin (NGAL), pro-matrix metalloproteinase-9 (pro-MMP-9) and their complex pro-MMP-9/NGAL in leukaemias. Cancers. 2014;6(2):796–812.CrossRefGoogle Scholar
  28. 28.
    Zhang Y, Fan Y, Mei Z. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification. Cancer Epidemiol. 2012;36(5):e294–e9.CrossRefGoogle Scholar
  29. 29.
    Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology. 2003;37(1):198–207.CrossRefGoogle Scholar
  30. 30.
    Wang YP, Yu GR, Lee MJ, Lee SY, Chu IS, Leem SH, et al. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway. Hepatology. 2013;58(4):1349–61.CrossRefGoogle Scholar
  31. 31.
    Jayaraman A, Roberts KA, Yoon J, Yarmush DM, Duan X, Lee K, et al. Identification of neutrophil gelatinase-associated lipocalin (NGAL) as a discriminatory marker of the hepatocyte-secreted protein response to IL-1β: a proteomic analysis. Biotechnol Bioeng. 2005;91(4):502–15.CrossRefGoogle Scholar
  32. 32.
    Cowland JB, Sørensen OE, Sehested M, Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1β, but not by TNF-α. J Immunol. 2003;171(12):6630–9.CrossRefGoogle Scholar
  33. 33.
    Moss SF, Blaser MJ. Mechanisms of disease: inflammation and the origins of cancer. Nat Clin Pract Oncol. 2005;2(2):90–7 quiz 1 p following 113.CrossRefGoogle Scholar
  34. 34.
    Nuntagowat C, Leelawat K, Tohtong R. NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation. Clin Exp Metastasis. 2010;27(5):295–305.CrossRefGoogle Scholar
  35. 35.
    Duvillard L, Ortega-Deballon P, Bourredjem A, Scherrer M-L, Mantion G, Delhorme J-B, et al. A case–control study of pre-operative levels of serum neutrophil gelatinase-associated lipocalin and other potential inflammatory markers in colorectal cancer. BMC Cancer. 2014;14(1):912.CrossRefGoogle Scholar
  36. 36.
    Friedl A, Stoesz S, Buckley P, Gould M. Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J. 1999;31(7):433–41.CrossRefGoogle Scholar
  37. 37.
    Di Carlo A. The enigmatic role of lipocalin 2 in human cancer. The multifunctional protein neutrophil gelatinase-associated lipocalin (NGAL) and its ambiguous role in human neoplasias. Prevent Res. 2012;2.Google Scholar
  38. 38.
    Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, Shostrom VK, Standop J, et al. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer. 2008;98(9):1540–7.CrossRefGoogle Scholar
  39. 39.
    Tong Z, Wu X, Ovcharenko D, Zhu J, Chen C-S, Kehrer JP. Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J. 2005;391(2):441–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Internal Medicine, Division of GastroenterologyVan Education and Research HospitalVanTurkey
  2. 2.Meram School of Medicine, Department of Internal Medicine, Division of GastroenterologyNecmettin Erbakan UniversityKonyaTurkey
  3. 3.Meram School of Medicine, Department of Internal MedicineNecmettin Erbakan UniversityKonyaTurkey

Personalised recommendations